Nonsteroidal anti-inflammatory drugs (NSAIDs) represent one of the most frequent causes of drug-induced urticaria/angioedema worldwide. Recent review articles have classified patients experiencing NSAID-induced urticaria/angioedema into different categories, including single reactors, multiple reactors, and multiple reactors with underlying chronic urticaria. Each of these categories requires a different clinical approach. The present article, written by a panel of experts, reports the main recommendations for the practical clinical management of patients with a history of urticaria/angioedema induced by multiple NSAID based on current knowledge.

Keywords:
NSAID, Urticaria, Cross-reactivity, Oral challenge tests, COX-1, COX-2, Nonsteroidal anti-inflammatory drug hypersensitivity
1.
Settipane RA, Constantine HP, Settipane GA: Aspirin intolerance and recurrent urticaria in normal adults and children. Allergy 1980;35:149–154.
2.
Mathison DA, Lumry WS, Stevenson DD, Curd JG: Aspirin in chronic urticaria and/or angioedema: studies of sensitivity and desensitisation (abstract). J Allergy Clin Immunol 1982;69(suppl):135.
3.
Stevenson DD, Simon RA: Sensitivity to aspirin and nonsteroidal anti-inflammatory drugs; in Middleton E, Reed CE, Ellis EF, et al (eds): Allergy: Principles and Practice, ed 4. St. Louis, Mosby, 1993, pp 1747–1765.
4.
Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R: Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or nonsteroidal anti-inflammatory drugs. Clin Exp Allergy 2002;32:397–400.
5.
Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A: Safety of cycloxygenase 2 inhibitors and increased leukotriene synthesis in chronic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003;139:1577–1582.
6.
Asero R: Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance. Clin Exp Dermatol 2007;32:661–663.
7.
Bae JS, Kin SH, Ye YM, Yoon HJ, et al: Significant association of FcεRIα promoter polymorphisms with aspirin-intolerant chronic urticaria. J Allergy Clin Immunol 2007;119:449–456.
8.
Kim SH, Ye YM, Palikhe NS, Kim JE, Park HS: Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol 2010;10:280–290.
9.
Sanchez-Borges M, Acevedo N, Vergara Jimenez S, Zabner-Oziel P, Monzon A, Caraballo L: The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J Investig Allergol Clin Immunol 2009;19:375–382.
10.
Szczeklik A: Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. Ann Allergy 1987;57:113–118.
11.
Papa G, Romano A, Del Bono A, et al: Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 1997;78:74–78.
12.
Pastorello E, Zara C, Riario-Sforza GG, et al: Atopy and intolerance of antimicrobial drugs increase the risk of reactions to acetaminophen and nimesulide in patients allergic to nonsteroidal anti-inflammatory drugs. Allergy 1998;53:880–884.
13.
Quaratino D, Romano A, Papa G, et al: Long-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patients. Ann Allergy Asthma Immunol 1997;79:47–50.
14.
Quiralte J, Blanco C, Castillo R, et al: Intolerance to nonsteroidal anti-inflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 1996;98:678–685.
15.
Sanchez-Borges M, Capriles-Hulett A: Atopy is a risk factor for nonsteroidal anti-inflammatory drug sensitivity. Ann Allergy Asthma Immunol 2000;84:101–106.
16.
Asero R: Detection of aspirin reactivity in patients with pyrazolones-induced skin disorders. Allergy 1998;53:214–215.
17.
Asero R: Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders. Ann Allergy Asthma Immunol 1999;82:554–558.
18.
Asero R: Multiple sensitivity to NSAID. Allergy 2000;55:893–894.
19.
Doña I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, et al: Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: pattern of response. Clin Exp Allergy 2011;41:86–95.
20.
Carmona MJ, Blanca M, Garcia A, et al: Intolerance to piroxicam in patients with adverse reactions to nonsteroidal antiinflammatory drugs. J Allergy Clin Immunol 1992;90:873–879.
21.
Andri L, Senna G, Betteli C, et al: Tolerability of nimesulide in aspirin-sensitive patients. Ann Allergy 1994;72:29–32.
22.
Ispano M, Fontana A, Scibilia J, Ortolani C: Oral challenge with alternative nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol in patients intolerant to these agents. Drugs 1993;46(suppl):253–256.
23.
Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR: Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201–204.
24.
Asero R: Tolerability of rofecoxib. Allergy 2001;56:916–917.
25.
Nettis E, Di Paola R, Ferrannini A, Tursi A: Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;88:331–334.
26.
Nettis E, Di Paola R, Ferrannini A, et al: Meloxicam in hypersensitivity to NSAIDs. Allergy 2001;56:803–804.
27.
Asero R: Chronic urticaria with multiple NSAID intolerance: is tramadol always a safe alternative analgesic? J Investig Allergol Clin Immunol 2003;13:55–58.
28.
Goksel O, Aydin O, Misirligil Z, Demirel YS, Bavbek S: Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. J Dermatol 2010;37:973–979.
29.
Quaratino D, Romano A, Di Fonso M, Papa G, Perrone MR, et al: Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2000;84:613–617.
30.
Asero R: Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria. Ann Allergy Asthma Immunol 2000;85:156–157.
31.
Perez C, Sanchez-Borges M, Capriles E: Pretreatment with montelukast blocks NSAID-induced urticaria and angioedema. J Allergy Clin Immunol 2001;108:1060–1061.
32.
Mastalerz L, Setkowicz M, Sanak M, Szczeklik A: Hypersensitivity to aspirin: common eicosanoids alterations in urticaria and asthma. J Allergy Clin Immunol 2004;113:771–775.
33.
Asero R: Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria. J Allergy Clin Immunol 2003;111:1095–1098.
34.
Sanchez-Borges M, Acevedo N, Caraballo L, Capriles-Hulett A, Caballero-Fonseca F: Increased total and mite-specific immunoglobulin E in patients with aspirin-induced urticaria and angioedema. J Investig Allergol Clin Immunol 2010;20:139–145.
35.
Stevenson DD, Sanchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclo-oxygenase enzymes (editorial). Ann Allergy Asthma Immunol 2001;87:1–4.
36.
Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al: Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) – classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy 2011;66:818–829.
37.
Viola M, Rumi G, Valluzzi RL, Gaeta F, Caruso C, Romano A: Assessing potential determinants of positive provocation tests in subjects with NSAID hypersensitivity. Clin Exp Allergy 2011;41:96–103.
38.
Blanca-Lopez N, Doña I, Torres MJ, Campo P, Rondón C, et al: Value of the clinical history in the diagnosis of NSAID hypersensitivity reactions induced by cross-intolerance. Clin Exp Allergy, in press.
39.
Asero R: Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2005;35:713–716.
40.
Malskat WSJ, van der Tas C, Knulst AC, Bruijnzeel-Koomen CA, Rockmann H: Aspirin tolerance in patients with NSAID hypersensitivity. Allergy 2010;65:1197–1198.
41.
Asero R: Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria. Ann Allergy Asthma Immunol 2006;97:187–189.
42.
Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase 1 rather than cyclo-oxygenase 2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563–7568.
43.
Doña I, Blanca-Lopez N, Jagemann LR, Torres MJ, Rondón C, et al: Response to a selective COX-2 inhibitor in patients with urticaria/angioedema induced by nonsteroidal anti-inflammatory drugs. Allergy 2011;66:1428–1433.
44.
Pleskow WW, Stevenson DD, Mathison DA, Simon RA, Schatz M, Zeiger RS: Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982;69:11–19.
45.
Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F: NSAID-induced urticaria and angioedema: a reappraisal of its clinical management. Am J Clin Dermatol 2002;3:599–607.
46.
Asero R: Cetirizine premedication prevents acute urticaria induced by weak COX-1 inhibitors in multiple NSAID reactors. Eur Ann Allergy Clin Immunol 2010;42:174–177.
47.
Celik G, Erkekol FO, Bavbek S, Dursun B, Misirligil Z: Long-term use and tolerability of cyclooxygenase-2 inhibitors in patients with analgesic intolerance. Ann Allergy Asthma Immunol 2005;95:33–37.
48.
Pagani M, Bonadonna P, Dama A, Senna GE, Vescovi PP, Antico A: Long-term tolerability of etoricoxib in different types of NSAID-intolerant subjects. Eur Ann Allergy Clin Immunol 2010;42:216–220.
49.
Nettis E, Colanardi MC, Ferrannini A, Vaccca A, Tursi A: Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005;95:438–442.
50.
Muratore L, Ventura M, Calogiuri G, Calcagnile F, Quarta E, Muratore M, Ferrannini A: Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammmatory drugs. Ann Allergy Asthma Immunol 2007;98:168–171.
51.
Viola M, Quaratino D, Gaeta F, Caruso C, Valluzzi R, Romano A: Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2007;143:103–108.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.